Finance

Lists
Why is NMRA down 7,75%?
Dive Deeper
NMRA:NASDAQ
Neumora Therapeutics Inc
USD 0,55
-7,75%
(-0,046) 1D
USD 0,54
-1,80% (-0,0099)
After hours
Closed: 1 Okt., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NMRA...
Open
USD 0,60
High
USD 0,62
Low
USD 0,54
Mkt. cap
102,69 m
Avg. vol.
1,41 m
Volume
2,85 m
52-wk high
USD 3,65
52-wk low
USD 0,54
EPS
-USD 1,23
Shares outstanding
187,90 m
No. of employees
63
Open
USD 0,60
High
USD 0,62
Low
USD 0,54
Mkt. cap
102,69 m
Avg. vol.
1,41 m
Volume
2,85 m
52-wk high
USD 3,65
52-wk low
USD 0,54
EPS
-USD 1,23
Shares outstanding
187,90 m
No. of employees
63
News stories
From web sources and news partners
About Neumora Therapeutics Inc
CEO-
Employees63
Founded2019
HeadquartersWatertown, Massachusetts, Verenigde State van Amerika
SectorPharmaceutical industry
Websiteneumoratx.com
Analyst ratings
Based on 5 analysts giving stock ratings to NMRA in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for NMRA in the last 3 months.
Highest
Current USD 0,55
USD 7,00 (+1 172,73%)
Average
USD 5,25 (+854,55%)
Lowest
USD 4,00 (+627,27%)
Analyst
Recommendation
Action
Price target
Projected
Date
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
USD 7,00
+1 172,7%
08/24/2026
Graig Suvannavejh
Mizuho Securities
Buy
Reiterated
USD 4,00
+627,3%
08/17/2026
Ami Fadia
Needham
Buy
Reiterated
USD 5,00
+809,1%
08/14/2026
Myles Minter
William Blair
Buy
Reiterated
-
-
08/14/2026
Brian Abrahams
RBC Capital
Buy
Maintained
USD 5,00
+809,1%
08/14/2026
Tessa Romero
J.P. Morgan
Sell
Maintained
-
-
05/26/2026
Paul Matteis
Stifel Nicolaus
Hold
Maintained
USD 3,00
+445,5%
05/12/2026
Yatin Suneja
Guggenheim
Buy
Maintained
USD 14,00
+2 445,5%
05/07/2026
Last report
14 Aug. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-USD 0,23 / -USD 0,24
+5,34%beat
Revenue / Est. (USD)
- / 0,00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
40,52 m
44,67 m
38,60 m
29,28 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
12,18 m
13,81 m
14,27 m
12,91 m
Operating expense
52,70 m
58,48 m
52,86 m
42,19 m
Total operating expenses
52,70 m
58,48 m
52,86 m
42,19 m
Operating income
-52,70 m
-58,48 m
-52,86 m
-42,19 m
Other non operating income
7,00 k
-269,00 k
59,00 k
-7,00 k
EBT including unusual items
-56,76 m
-59,45 m
-53,43 m
-43,08 m
EBT excluding unusual items
-51,76 m
-59,45 m
-53,43 m
-43,08 m
Income tax expense
-
-
30,00 k
-
Effective tax rate
-
-
-0,06%
-
Other operating expenses
-
-
-
-
Net income
-56,76 m
-59,45 m
-53,46 m
-43,08 m
Net profit margin
-
-
-
-
Earnings per share
-0,35
-0,35
-0,30
-0,23
Interest and investment income
1,68 m
1,34 m
1,23 m
935,00 k
Interest expense
-747,00 k
-2,04 m
-1,85 m
-1,82 m
Net interest expenses
938,00 k
-701,00 k
-623,00 k
-885,00 k
Depreciation and amortization charges
-
-
-
-
EBITDA
-52,68 m
-58,47 m
-52,86 m
-42,18 m
Gain or loss from assets sale
-62,00 k
264,00 k
-71,00 k
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme